Results 141 to 150 of about 4,279 (197)

Diphtheria-like Pseudomembranous <i>Corynebacterium striatum</i> Chronic Infection of Left Ventricular Assist Device Driveline Bridged to Heart Transplantation with Dalbavancin Treatment. [PDF]

Reports (MDPI)
Lupia T, Casarotto M, Mornese Pinna S, Corcione S, Bondi A, Boffini M, Rinaldi M, De Rosa FG.   +7 more
europepmc   +1 more source

Proactive Therapeutic Drug MONiToring to Guide Suppressive Antibiotic Therapy with DALBAvaNcin ( > 12 weeks) in Osteoarticular Infections (MONTALBANO). [PDF]

J Bone Jt Infect
Mariani C, Passerini M, Galli L, Covizzi A, Colaneri M, Offer M, Faenzi M, Merli S, Landonio S, Fusi M, Dolci A, Gori A, Cattaneo D.   +12 more
europepmc   +1 more source

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. [PDF]

JAMA
Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V, Cosgrove SE, Jenkins TC, Liu C, Sharma S, Zaharoff S, Wahid L, Renard VJ, Cook P, Raad I, Hachem R, Chaftari AM, Sims M, DeMarco C, Miller LG, McCarthy MW, Morse CG, Lucasti C, Forrest GN, Cherabuddi K, Polk C, Fazili T, Rupp ME, Thompson GR, Kim K, Strnad L, Schnee AE, McKinnell JA, Ramesh M, Silveira FP, McCarty TP, Lee TC, McDonald EG, Paolino K, Wiegand K, Wall A, Riccobene T, Patel R, Rappo U, Evans S, Chambers HF, Fowler VG, Holland TL, Antibacterial Resistance Leadership Group.   +48 more
europepmc   +1 more source

Gerbode defect resulting from ineffective treatment of infective endocarditis: a case report. [PDF]

Cardiovasc Ultrasound
Carter KS, Reed P, Gentry J.
europepmc   +1 more source

Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting. [PDF]

Infection
Darlow CA, Parsons J, Lucy D, Li A, Ratcliffe L, Todd S, Wong N.   +6 more
europepmc   +1 more source

Methicillin-resistant <i>Staphylococcus aureus</i> and vancomycin-resistant <i>Enterococcus faecium</i> infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data and key evidence gaps. [PDF]

Lancet Reg Health West Pac
Gwee A, Bannister S, Best E, Carr J, Harwood K, Lai T, Lei A, Lutui F, McMullan B, Mostaghim M, Voss L, Weerdenburg H, Williams P, Wilkins A, Yeoh D, KIDS DOSE group.   +15 more
europepmc   +1 more source

Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? [PDF]

J Antimicrob Chemother
MacPhail A, Attwood LO, Rogers BA.
europepmc   +1 more source

Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center? [PDF]

Fed Pract
Hanks D, Jodlowski TZ, Madaras-Kelly K, Diaz J, Vietri N.   +4 more
europepmc   +1 more source